Coronary disease & ACS

Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk: A Randomized Clinical Trial

JAMA CardiolPublished Prespecified secondary analysis of the FIRE randomised clinical trial

Primary result · Primary end point in HBR (subgroup)Result — go to the resultHazard ratio 0.73 95% CI 0.55–0.96

Authors' conclusion

HBR status is prevalent among older patients with MI, significantly increasing the likelihood of adverse events. Physiology-guided complete revascularization emerges as an effective strategy, in comparison with culprit-only revascularization, for mitigating ischemic adverse events, including cardiovascular death and MI.

Study context

Population
Patients ≥75 years with myocardial infarction (MI) and multivessel disease, 34 European centres, July 2019–October 20211,025 (71%) met high bleeding risk (HBR) criteria
Participants
1,445 patients
Comparison
Physiology-guided complete revascularization vs culprit-only strategy, by HBR status
Primary endpoint
Composite of:
  • Death
  • MI
  • Stroke
  • Revascularization
Follow-up
1 year
Methodological detailsinvestigator-initiated, open-label, multicentre, 34 European centres
  • Investigator-initiated
  • Open-label
  • Multicentre
  • 34 European centres

Primary result

Primary end point in HBR (subgroup)

Hazard ratio

0.73

95% CI 0.55–0.96

Complete revascularization vs Culprit-only
HR 0.73 (95% CI 0.55–0.96)

As reported in the abstract

Secondary outcomes

OutcomeHR (95% CI)
Primary end point, HBR vs non-HBR (prognosis) · 1 year2.01 (1.47–2.76)
CV death or MI, HBR vs non-HBR (prognosis)1.89 (1.26–2.83)

Safety

OutcomeHR (95% CI)
BARC types 3 to 5 bleeding, HBR vs non-HBR3.28 (1.40–7.64)

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk: A Randomized Clinical Trial. JAMA Cardiol. Published 1 June 2024. doi:10.1001/jamacardio.2024.0804

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.